FDA Meeting on Ersodetug Sparks 12% Stock Rally Amid Lingering Clinical Doubts

What happened

Rezolute's stock surged 12% after an FDA meeting highlighted ersodetug data and outlined next steps, providing a brief respite from the 80-90% collapse following the failed Phase 3 sunRIZE trial in congenital hyperinsulinism last December. The meeting likely addressed potential salvage pathways for the congenital indication and updates on the streamlined Phase 3 upLIFT trial in tumor-induced hyperinsulinism, which remains the company's most credible near-term approval hope. However, the DeepValue master report cautions that regulatory skepticism is elevated post-failure, with the congenital pathway still speculative and no FDA endorsement yet. Despite a cash runway into mid-2027, annual burn rates near $70 million and ongoing litigation overhangs persist, keeping the risk profile binary. Investors should view this rally as a speculative bounce driven by incremental news rather than a fundamental shift in the company's distressed single-asset narrative.

Implication

The FDA meeting offers temporary relief by confirming ongoing dialogue, but it doesn't alter the binary risk profile, as Rezolute's fate hinges on upLIFT's success in 2H26 and unclear congenital salvage prospects. Cash reserves provide a runway, but high burn and litigation risks could force dilutive financing or strategic moves if clinical outcomes disappoint. The upLIFT trial is now the primary value driver, and any delays or negative data could trigger another sharp decline, emphasizing the need for disciplined cost management. Investors should closely monitor forthcoming FDA feedback details and upLIFT enrollment updates, as these will determine whether the company can secure any approval before cash dwindles. Overall, this news reinforces the 'WAIT' recommendation, preserving capital until regulatory clarity or cheaper entry points improve the asymmetric risk-reward.

Thesis delta

The FDA meeting slightly reduces uncertainty by providing visibility into next steps, but it doesn't shift the core thesis that Rezolute remains a high-risk, single-asset biotech with speculative congenital prospects and binary dependence on upLIFT. The 'WAIT' rating stays unchanged, as meaningful thesis improvement requires concrete FDA endorsements or positive trial data, neither of which are confirmed here.